Hongxiang Du,Tianhan Xu,Sihui Yu et al.
Hongxiang Du et al.
Mitochondria are dynamic organelles that are essential for cellular energy generation, metabolic regulation, and signal transduction. Their structural complexity enables adaptive responses to diverse physiological demands. In cancer, mitoch...
Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma [0.03%]
靶向AKR1B1抑制代谢重编程以逆转肝细胞癌的全身治疗耐药性
Qi Wang,Juan Liu,Ming Yang et al.
Qi Wang et al.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and resistance to systemic therapies remains a significant clinical challenge. This study investigated the mechanisms by which metabolic reprogramming contribute...
Claudia Galassi,Gwenola Manic,Manel Esteller et al.
Claudia Galassi et al.
Gene expression is finely controlled by the abundance and activation status of transcription factors and their regulators, as well as by a number of reversible modifications of DNA and histones that are commonly referred to as epigenetic ma...
Impact of allogeneic dental pulp stem cell injection on tissue regeneration in periodontitis: a multicenter randomized clinical trial [0.03%]
同种异体牙髓干细胞注射对牙周炎组织再生的影响：多中心随机临床试验
Yi Liu,Yitong Liu,Jingchao Hu et al.
Yi Liu et al.
Periodontitis causes the destruction of tooth-supporting tissues, and current therapies for periodontal regeneration are invasive. In this study, a human dental pulp stem cell (DPSC; hDP-MSC) injection was developed to promote periodontal r...
Randomized Controlled Trial
Signal transduction and targeted therapy. 2025 Jul 31;10(1):239. DOI:10.1038/s41392-025-02320-w 2025
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches [0.03%]
癌症免疫逃逸：机制和前沿治疗策略
Muhammad Tufail,Can-Hua Jiang,Ning Li
Muhammad Tufail
Immune evasion represents a significant challenge in oncology. It allows tumors to evade immune surveillance and destruction, thereby complicating therapeutic interventions and contributing to suboptimal patient outcomes. This review addres...
Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024 [0.03%]
2022年12月至2024年4月中国西南地区突破感染后针对COVID-19奥密克戎亚变体的中和抗体动态变化
Yongquan He,Yi Yin,Yi Zhang et al.
Yongquan He et al.
From December 2022 to January 2023, the SARS-CoV-2 Omicron BA.5/BF.7 variant significantly impacted mainland China. While most COVID-19 patients experienced mild symptoms and were treated as outpatients or at home, some cases progressed to ...
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights [0.03%]
间充质基质细胞治疗失代偿期肝硬化的剂量递增研究：I 期 a/Ib 结果和免疫调节见解
Lei Shi,Ziying Zhang,Song Mei et al.
Lei Shi et al.
Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal d...
Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions [0.03%]
核受体的信号通路、生物功能及药物干预在健康与疾病中的作用
Ping Jin,Xirui Duan,Zhao Huang et al.
Ping Jin et al.
Nuclear receptors (NRs) are a large family of ligand-dependent transcription factors that regulate the expression of a wide range of target genes in response to endogenous and exogenous ligands, including steroid hormones, thyroid hormone, ...
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder [0.03%]
星形胶质细胞γ-氨基丁酸失调节作为创伤后应激障碍的治疗靶点
Sujung Yoon,Woojin Won,Suji Lee et al.
Sujung Yoon et al.
Post-traumatic stress disorder (PTSD) remains a debilitating psychiatric condition with limited pharmacological treatment options. Identifying novel therapeutic targets is critical for addressing its unmet clinical needs. Through our compre...
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06) [0.03%]
复发/难治性弥漫大B细胞淋巴瘤的遗传亚型导向免疫化疗：一项II期非随机临床研究（GUIDANCE-06）
Yi-Ge Shen,Qing Shi,Wei Tang et al.
Yi-Ge Shen et al.
Improving the outcome of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remained an unmet need. The aim of this single-center, phase 2 trial was to evaluate the efficacy and safety of genetic subtype-guided immunochemother...